Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry
Key result
Guideline-directed medical therapy use was high in a European registry of 10,162 heart failure patients, including beta-blockers in 92% and RAS inhibitors in 89% of HFrEF patients.
Why the study?
The study was conducted to analyse baseline characteristics and guideline-directed medical therapy use and decisions across acute and outpatient heart failure phenotypes.
What are the baseline characteristics and rates of guideline-directed medical therapy use in patients with acute and chronic heart failure in Europe?
Population
10 162 patients with acute HF or outpatient HF across 41 European or ESC-affiliated countries
Comparison
AHF vs outpatient HF, de novo vs pre-existing HF, and across HFrEF, HFmrEF, and HFpEF
Design
Multicentre multinational registry
Authors
Discussion
Loading...
Member takes
Implication
Supports high GDMT adoption in European HF care; leaves open effects on outcomes and generalizability beyond cardiology centers.
Study Design
Type
Observational (n=10,162)
Multicenter
Yes
Structured PICO
What are the baseline characteristics and rates of guideline-directed medical therapy use in patients with acute and chronic heart failure in Europe?
P
Population
10,162 patients with acute or outpatient heart failure across the ejection fraction spectrum enrolled from 220 European centers to assess guideline-directed medical therapy use.
E
Exposure
Guideline-directed medical therapy (GDMT) use and decision making
O
Outcome
Baseline characteristics and guideline-directed medical therapy (GDMT) use and decisions
The ESC EORP Heart Failure III Registry demonstrates high rates of guideline-directed medical therapy use and initiation in European cardiology centers across the spectrum of heart failure ejection fractions.
Cite This Study
Lund et al. (2024) conducted an observational in Heart failure (n=10,162). Guideline-directed medical therapy (GDMT) was evaluated on Use of guideline-directed medical therapy (GDMT) after acute heart failure event or outpatient visit. Guideline-directed medical therapy use was high in a European registry of 10,162 heart failure patients, including beta-blockers in 92% and RAS inhibitors in 89% of HFrEF patients.